We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: cardiovascular disease
MedXY News
EnglishTag

cardiovascular disease

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Beyond the Clot: Novel Proteomic Markers Redefine Venous Thromboembolism Risk
Cardiologybiomarkerscardiovascular disease

Beyond the Clot: Novel Proteomic Markers Redefine Venous Thromboembolism Risk

By MedXY|Mar 28, 2026

This large-scale proteomic analysis identifies 15 novel protein markers for venous thromboembolism, offering new insights into the roles of immunity and extracellular matrix regulation in VTE pathogenesis beyond traditional coagulation path

Beyond Statins: The Evolution and Clinical Impact of PCSK9 Inhibition in Cardiovascular Risk Management
Cardiologycardiovascular diseaseLDL Cholesterol

Beyond Statins: The Evolution and Clinical Impact of PCSK9 Inhibition in Cardiovascular Risk Management

By MedXY|Mar 21, 2026

This article explores the transformation of lipid management through PCSK9 inhibitors. From genetic discovery to landmark cardiovascular outcomes trials, we examine how monoclonal antibodies, RNA interference, and gene editing are redefinin

Is Semaglutide Worth the Cost? Evaluating the Economic Reality of GLP-1s for Heart Disease Prevention
Cardiologycardiovascular diseaseCost-Effectiveness

Is Semaglutide Worth the Cost? Evaluating the Economic Reality of GLP-1s for Heart Disease Prevention

By MedXY|Mar 20, 2026

A comprehensive simulation study evaluates the cost-effectiveness of semaglutide for secondary cardiovascular prevention in US adults without diabetes, finding significant health benefits but highlighting the need for price reductions to en

Levothyroxine Monotherapy in Midlife Women: Long-Term SWAN Data Reassures on Cardiovascular Safety
Diabetes & Endocrinologycardiovascular diseaseHypothyroidism

Levothyroxine Monotherapy in Midlife Women: Long-Term SWAN Data Reassures on Cardiovascular Safety

By MedXY|Mar 12, 2026

A longitudinal analysis from the SWAN study indicates that women treated with levothyroxine for hypothyroidism do not face a higher risk of cardiovascular events compared to those without thyroid disease, providing clinical reassurance for

GLP-1 Receptor Agonists in Primary Prevention: Emulated Clinical Trial Predicts 22% Reduction in Cardiovascular Events
Cardiologycardiovascular diseaseGLP-1RA

GLP-1 Receptor Agonists in Primary Prevention: Emulated Clinical Trial Predicts 22% Reduction in Cardiovascular Events

By MedXY|Mar 12, 2026

This emulation study applies SELECT trial data to over 600,000 individuals, suggesting that GLP-1RAs could significantly reduce 10-year cardiovascular risk in high-risk obese populations without existing disease, offering a potential 22% re

Clinical Factors and Biomarkers During Pregnancy and Risk of Cardiovascular Disease: Leveraging the ‘Natural Stress Test’
Cardiologybiomarkerscardiovascular disease

Clinical Factors and Biomarkers During Pregnancy and Risk of Cardiovascular Disease: Leveraging the ‘Natural Stress Test’

By MedXY|Mar 11, 2026

This review synthesizes findings on how pregnancy biomarkers, particularly sFlt-1 and hs-cTnI, serve as early indicators of long-term maternal cardiovascular risk, offering a unique window for sex-specific prevention.

Beyond the Binary: The Evolving Consensus on the Spectrum of Primary Aldosteronism and Cardiovascular Risk
Cardiologyatrial fibrillationcardiovascular disease

Beyond the Binary: The Evolving Consensus on the Spectrum of Primary Aldosteronism and Cardiovascular Risk

By MedXY|Mar 7, 2026

Recent data from the ARIC study and emerging expert consensus are redefining primary aldosteronism. Rather than a rare, all-or-nothing condition, it is now viewed as a broad spectrum where even subclinical elevations significantly increase

Obesity Severity and Cardiovascular Trajectories: Insights from the Cross-Cohort Collaboration
Cardiologycardiovascular diseaseheart failure

Obesity Severity and Cardiovascular Trajectories: Insights from the Cross-Cohort Collaboration

By MedXY|Mar 2, 2026

This review synthesizes findings from a 21- **Compiling final edits** Now that I’ve structured the article, I’m focusing on the final touches, particularly the content for the “Highlights,” “Expert Commentary,&

The Rising Tide of Cardiovascular Disease: AHA’s 2050 Forecast for Women’s Heart Health
CardiologyCardiologycardiovascular disease

The Rising Tide of Cardiovascular Disease: AHA’s 2050 Forecast for Women’s Heart Health

By MedXY|Mar 2, 2026

A major AHA scientific statement forecasts a significant increase in cardiovascular disease and risk factors among U.S. women by 2050. It highlights rising rates of obesity and hypertension while emphasizing the urgent need for targeted int

Beyond Information Delivery: Why Survivorship Care Plans Alone May Not Reduce Cardiovascular Risk in Cancer Survivors
Cardiologycardiovascular diseasechildhood cancer

Beyond Information Delivery: Why Survivorship Care Plans Alone May Not Reduce Cardiovascular Risk in Cancer Survivors

By MedXY|Feb 24, 2026

This article examines the CHIIP study, a randomized clinical trial evaluating whether survivorship care plan-based counseling improves cardiovascular risk factor control in childhood cancer survivors. Findings suggest that while documentati

Pregnancy as a Window to Longevity: Maternal Biomarkers at 29 Weeks Predict Long-Term Cardiovascular Risk
Cardiologybiomarkerscardiovascular disease

Pregnancy as a Window to Longevity: Maternal Biomarkers at 29 Weeks Predict Long-Term Cardiovascular Risk

By MedXY|Feb 22, 2026

A Danish cohort study demonstrates that specific pregnancy biomarkers, particularly sFlt-1 and hs-cTnI measured at 29 weeks, significantly enhance the prediction of long-term cardiovascular disease risk in women, independent of traditional

Semaglutide for Secondary CVD Prevention: Evaluating the Price of Clinical Success
Cardiologycardiovascular diseaseCost-Effectiveness

Semaglutide for Secondary CVD Prevention: Evaluating the Price of Clinical Success

By MedXY|Feb 5, 2026

A simulation study reveals that while semaglutide significantly reduces cardiovascular events in adults with obesity, its current cost exceeds traditional cost-effectiveness thresholds, requiring an 18% price reduction for broader economic

Haptoglobin 1-1 and Low Protein Levels: Identifying the Lowest Cardiovascular Risk in Type 2 Diabetes
Cardiologycardiovascular diseaseFenofibrate

Haptoglobin 1-1 and Low Protein Levels: Identifying the Lowest Cardiovascular Risk in Type 2 Diabetes

By MedXY|Feb 3, 2026

A FIELD sub-study reveals that while higher haptoglobin levels increase cardiovascular risk—particularly in those with the HP 1-1 phenotype—fenofibrate’s protective effects remain consistent regardless of haptoglobin status, challengi

Oral Semaglutide Slows eGFR Decline in Patients with Type 2 Diabetes and High Cardiovascular Risk: Insights from the SOUL Trial
Cardiologycardiovascular diseasechronic kidney disease

Oral Semaglutide Slows eGFR Decline in Patients with Type 2 Diabetes and High Cardiovascular Risk: Insights from the SOUL Trial

By MedXY|Feb 2, 2026

The SOUL trial demonstrates that oral semaglutide significantly slows the annual decline of estimated glomerular filtration rate (eGFR) in patients with type 2 diabetes and cardiovascular disease, despite not meeting the primary composite k

Lipoprotein(a) and the 30-Year Horizon: Redefining Long-Term Cardiovascular and Stroke Risk in Women
Cardiologycardiovascular diseaseischemic stroke

Lipoprotein(a) and the 30-Year Horizon: Redefining Long-Term Cardiovascular and Stroke Risk in Women

By MedXY|Jan 25, 2026

Longitudinal data from the Women’s Health Study reveal that elevated Lipoprotein(a) is a potent, independent predictor of myocardial infarction and ischemic stroke over three decades, suggesting a critical need for universal screening in pr

Interleukin-6 Inhibition: A New Frontier in Reducing Residual Cardiovascular and Renal Risk
Cardiologycardiovascular diseasechronic kidney disease

Interleukin-6 Inhibition: A New Frontier in Reducing Residual Cardiovascular and Renal Risk

By MedXY|Jan 16, 2026

Recent clinical evidence identifies Interleukin-6 (IL-6) as a critical driver of cardiovascular events. The ZEUS trial and recent LoDoCo2 analyses suggest that targeting IL-6 with ziltivekimab may significantly reduce risk for patients with

Bone Metabolism Biomarkers: A New Frontier in Predicting Cardiovascular Risk for Diabetes and Renal Disease
Cardiologybiomarkerscardiovascular disease

Bone Metabolism Biomarkers: A New Frontier in Predicting Cardiovascular Risk for Diabetes and Renal Disease

By MedXY|Jan 9, 2026

Recent studies demonstrate that biomarkers of bone metabolism, particularly the OPG/TRAIL ratio, are powerful predictors of cardiovascular disease and mortality in patients with type 2 diabetes and chronic kidney disease, offering improved

Large Clonal Hematopoiesis Clones Drive Myocardial Infarction Risk in People With HIV
Cardiologycardiovascular diseaseClonal hematopoiesis

Large Clonal Hematopoiesis Clones Drive Myocardial Infarction Risk in People With HIV

By MedXY|Jan 7, 2026

Data from the REPRIEVE trial indicates that while general clonal hematopoiesis is common in people with HIV, only large clones (VAF ≥10%) significantly elevate the risk for myocardial infarction and revascularization, independent of traditi

SGLT2 Inhibitors Demonstrate Cardioprotective Benefits Even in Low-Risk Type 2 Diabetes Populations: Insights from a Causal Forest Analysis
Cardiologycardiovascular diseasemachine learning

SGLT2 Inhibitors Demonstrate Cardioprotective Benefits Even in Low-Risk Type 2 Diabetes Populations: Insights from a Causal Forest Analysis

By MedXY|Jan 7, 2026

A nationwide target trial emulation study reveals that SGLT2 inhibitors provide cardiovascular benefits across a broader range of patients than previously recognized, with benefit more closely tied to individual metabolic traits than tradit

Integrating Metabolomics and Polygenics with SCORE2: A New Frontier in Cardiovascular Risk Stratification
Cardiologycardiovascular diseasemetabolomics

Integrating Metabolomics and Polygenics with SCORE2: A New Frontier in Cardiovascular Risk Stratification

By MedXY|Jan 5, 2026

A large-scale UK Biobank study demonstrates that combining NMR metabolomics, polygenic risk scores, and clinical biomarkers with SCORE2 significantly enhances cardiovascular risk prediction, potentially doubling the number of prevented even

Prev
2 / 4
1234
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities